Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shirishadi compound is a polyherbal Ayurvedic preparation investigated for its therapeutic potential in managing asthma and allergic disorders. It is composed of extracts from three plants: Albizia lebbeck (Shirisha), Cyperus rotundus (Nagarmotha), and Solanum xanthocarpum or Solanum surattense (Kantakari). Clinical studies have evaluated its efficacy in both acute and chronic bronchial asthma when administered as a nebulized aerosol and orally. Research suggests that the compound exhibits multiple pharmacological activities, including bronchodilator, anti-inflammatory, antihistaminic (H1 receptor antagonism), mast cell stabilizing, and immunomodulatory effects. These properties are attributed to the synergistic action of its herbal constituents, which contain phytochemicals like saponins, flavonoids, and alkaloids. For instance, studies on guinea pigs demonstrated that the compound provided significant protection against histamine-induced bronchoconstriction. The formulation aims to offer an alternative remedy for respiratory conditions by addressing underlying inflammatory and allergic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shirishadi compound.